Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1992 4
1993 2
1994 2
1995 1
1996 2
1997 3
1998 4
1999 5
2000 9
2001 7
2002 4
2003 2
2004 6
2005 5
2006 6
2007 5
2008 12
2009 13
2010 13
2011 2
2012 4
2013 4
2014 10
2015 4
2016 1
2018 1
2019 1
2020 4
2021 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

127 results
Results by year
Filters applied: . Clear all
Page 1
SAR439859, a Novel Selective Estrogen Receptor Degrader (SERD), Demonstrates Effective and Broad Antitumor Activity in Wild-Type and Mutant ER-Positive Breast Cancer Models.
Shomali M, Cheng J, Sun F, Koundinya M, Guo Z, Hebert AT, McManus J, Levit MN, Hoffmann D, Courjaud A, Arrebola R, Cao H, Pollard J, Lee JS, Besret L, Caron A, Bangari DS, Abecassis PY, Schio L, El-Ahmad Y, Halley F, Tabart M, Certal V, Thompson F, McCort G, Filoche-Rommé B, Cheng H, Garcia-Echeverria C, Debussche L, Bouaboula M. Shomali M, et al. Among authors: garcia echeverria c. Mol Cancer Ther. 2021 Feb;20(2):250-262. doi: 10.1158/1535-7163.MCT-20-0390. Epub 2020 Dec 11. Mol Cancer Ther. 2021. PMID: 33310762 Free article.
Preclinical Activity of SAR408701: A Novel Anti-CEACAM5-maytansinoid Antibody-drug Conjugate for the Treatment of CEACAM5-positive Epithelial Tumors.
Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, Cameron B, Rival P, Devaud C, Prades C, Bouchard H, Cassé A, Henry C, Amara C, Brillac C, Ferrari P, Maçon L, Lacoste E, Combeau C, Beys E, Naimi S, García-Echeverría C, Mayaux JF, Blanc V. Decary S, et al. Among authors: garcia echeverria c. Clin Cancer Res. 2020 Dec 15;26(24):6589-6599. doi: 10.1158/1078-0432.CCR-19-4051. Epub 2020 Oct 12. Clin Cancer Res. 2020. PMID: 33046521 Free article.
Monovalent protein-degraders - Insights and future perspectives.
Cornella-Taracido I, Garcia-Echeverria C. Cornella-Taracido I, et al. Among authors: garcia echeverria c. Bioorg Med Chem Lett. 2020 Jun 15;30(12):127202. doi: 10.1016/j.bmcl.2020.127202. Epub 2020 Apr 18. Bioorg Med Chem Lett. 2020. PMID: 32331933 Review.
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials.
Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR. Fritsch C, et al. Among authors: garcia echeverria c. Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7. Mol Cancer Ther. 2014. PMID: 24608574 Free article.
The drug annotations series.
Zablocki J, Garcia-Echeverria C. Zablocki J, et al. Among authors: garcia echeverria c. J Med Chem. 2013 Sep 12;56(17):6541. doi: 10.1021/jm401297r. Epub 2013 Sep 3. J Med Chem. 2013. PMID: 24000804 No abstract available.
Antibody-drug conjugates—a new wave of cancer drugs.
Bouchard H, Viskov C, Garcia-Echeverria C. Bouchard H, et al. Among authors: garcia echeverria c. Bioorg Med Chem Lett. 2014 Dec 1;24(23):5357-63. doi: 10.1016/j.bmcl.2014.10.021. Epub 2014 Oct 13. Bioorg Med Chem Lett. 2014. PMID: 25455482 Free article. Review.
PI3K inhibitors for cancer treatment: where do we stand?
Maira SM, Stauffer F, Schnell C, García-Echeverría C. Maira SM, et al. Among authors: garcia echeverria c. Biochem Soc Trans. 2009 Feb;37(Pt 1):265-72. doi: 10.1042/BST0370265. Biochem Soc Trans. 2009. PMID: 19143644 Review.
Blocking the PI3K/PKB pathway in tumor cells.
Stauffer F, Holzer P, García-Echeverría C. Stauffer F, et al. Among authors: garcia echeverria c. Curr Med Chem Anticancer Agents. 2005 Sep;5(5):449-62. doi: 10.2174/1568011054866937. Curr Med Chem Anticancer Agents. 2005. PMID: 16178772 Review.
127 results